Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
1-20 of 1,782 trials

Adrenocortical Carcinoma: Mitotane Treatment Study

We are comparing standard mitotane therapy to mitotane combined with chemotherapy for patients at high risk of cancer recurrence after surgery. This study aims to find out which treatment helps patients live longer and maintain a better quality of life.

Adrenocortical Carcinoma6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Hodgkin Lymphoma: A2VD vs. ABVD Treatment Study

We are comparing two treatment options for patients with untreated early-stage Hodgkin lymphoma to see which may improve survival and reduce side effects. This study uses advanced imaging techniques to guide treatment decisions.

Classical Hodgkin LymphomaConfirmation phase (III)No PlaceboStandard MedicinesOncology

Nalmefene for Reducing Cravings in Behavioral Addictions

We are studying whether nalmefene can help reduce craving intensity in people with behavioral addictions, such as gambling and food addiction, when added to their usual treatment.

Behavioural AddictionConfirmation phase (III)≤5 visitsStandard MedicinesCost Reimbursement

Cholangiocarcinoma: Comparing RFA and PDT Treatments

We are studying whether radiofrequency ablation or photodynamic therapy helps patients with cholangiocarcinoma live longer. We’ll also look at how these treatments affect quality of life and any potential side effects.

Hilar Cholangiocarcinoma>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGastroenterologyOncology

Corneal Transplantation: Optimized Immunosuppression Study

We are testing new immunosuppressive protocols for patients receiving corneal transplants to see if they can reduce eye pressure and cell loss. We also want to understand patient experiences and the cost-effectiveness of these treatments.

Corneal Graft Failure1-2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementOphthalmology

Coronary Artery Disease Screening: Heart CT in Type 2 Diabetes

We are studying whether a heart CT scan can help find early signs of heart disease in people with type 2 diabetes. This may lead to better treatment options and improved heart health.

Type 2 DiabetesMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementCardiologyDiabetologyEndocrinology

Cardiac AL Amyloidosis: [18F]florbetaben PET Imaging Study

We are evaluating a new imaging technique to improve the diagnosis of cardiac AL amyloidosis in patients. This study will help us understand how well it works compared to current diagnostic methods.

Cardiac AmyloidosisAL AmyloidosisATTR Amyloidosis>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInternal Medicine

Hydrochlorothiazide for Polycystic Kidney Disease Patients

We are studying whether adding hydrochlorothiazide to tolvaptan can help slow kidney function decline in people with polycystic kidney disease. This trial also looks at how this combination affects quality of life and treatment tolerability.

Autosomal Dominant Polycystic Kidney Disease>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteInternal MedicineNephrology

Esophageal Achalasia: PPI Treatment Study

We are exploring whether routine use of a medication for acid reflux is better than using it only when needed after a procedure for esophageal achalasia. This study aims to improve treatment outcomes and quality of life for patients.

Esophageal Achalasia1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyInternal Medicine

Kidney Transplant: Imlifidase for Highly Sensitized Children

We are studying whether imlifidase can help children with high sensitization receive a kidney transplant by improving compatibility with the donor. This trial will also look at kidney function and overall safety of the treatment.

Kidney Transplant Rejection>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNephrology

Rheumatoid Arthritis: Abatacept vs. TNF Inhibitors

We are comparing a new treatment strategy using abatacept to the standard TNF inhibitors for patients with rheumatoid arthritis. The goal is to see which approach helps more patients achieve remission.

Rheumatoid Arthritis6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineRheumatology

Ulcerative Colitis: SAR443122 Study

We are testing different doses of SAR443122 in adults with moderate to severe ulcerative colitis to see how well it works and its safety. The study will also look at improvements in symptoms and quality of life.

Ulcerative Colitis1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Acute Myeloid Leukemia: CPX-351 vs. Standard Chemotherapy

We are studying whether a new treatment called CPX-351 can help patients with specific types of acute myeloid leukemia achieve better remission compared to standard chemotherapy. This trial focuses on patients with de novo intermediate or adverse risk AML.

Acute Myeloid Leukemia>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Kidney Transplant: Belatacept vs. Traditional Immunosuppressants

We are studying if replacing standard medications with belatacept helps kidney transplant patients with early graft dysfunction. The goal is to see if this approach improves kidney function and reduces rejection risks.

Kidney Transplant1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesNephrology

Chronic Lymphocytic Leukemia: Venetoclax and Epcoritamab Study

We are studying a combination of venetoclax and epcoritamab in patients with relapsed or refractory CLL or SLL. The goal is to see if this treatment improves disease control and overall survival compared to existing options.

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Uveal Melanoma: Adjuvant Melatonin Study

We are investigating whether nightly melatonin can help reduce the spread of uveal melanoma and improve survival rates. This study is for patients diagnosed with this type of eye cancer.

Uveal MelanomaConfirmation phase (III)No PlaceboStandard MedicinesOncologyOphthalmology

Crohn's Disease: Comparing Biological Therapies After Surgery

We are studying two ways to start biological therapy after surgery for Crohn's disease to see which better prevents disease recurrence. This trial involves adults who have had an ileocolonic resection.

Crohn's Disease1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyInternal Medicine

Etrasimod for Adolescents with Ulcerative Colitis

We are studying whether etrasimod can help adolescents aged 12 to 17 with moderately to severely active ulcerative colitis achieve remission. The trial will also look at the safety and how the body processes the medication.

Ulcerative Colitis1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Postoperative Pain Management: Genetic Testing for Tramadol

We are studying whether genetic testing can help tailor tramadol treatment for better pain relief and fewer side effects after surgery. This trial also compares tramadol with another pain medication to find the most effective option.

PharmacogeneticsTherapeutic Techniques for Acute Postoperative PainMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineNeurologyPsychiatry

Heart Attack Recovery: Dabigatran vs. Vitamin K Antagonist

We are studying whether the medication Dabigatran helps patients with blood clots in the heart after a heart attack recover better than a traditional treatment. This trial looks at how well each treatment resolves the clot and prevents complications.

STEMI (ST Elevation Myocardial Infarction)Left Ventricular Thrombosis>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine